BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Shi L, Wang S, Zangari M, Xu H, Cao TM, Xu C, Wu Y, Xiao F, Liu Y, Yang Y, Salama M, Li G, Tricot G, Zhan F. Over-expression of CKS1B activates both MEK/ERK and JAK/STAT3 signaling pathways and promotes myeloma cell drug-resistance. Oncotarget 2010;1:22-33. [PMID: 20930946 DOI: 10.18632/oncotarget.105] [Cited by in Crossref: 66] [Cited by in F6Publishing: 74] [Article Influence: 6.6] [Reference Citation Analysis]
Number Citing Articles
1 Manier S, Salem K, Glavey SV, Roccaro AM, Ghobrial IM. Genomic Aberrations in Multiple Myeloma. In: Roccaro AM, Ghobrial IM, editors. Plasma Cell Dyscrasias. Cham: Springer International Publishing; 2016. pp. 23-34. [DOI: 10.1007/978-3-319-40320-5_3] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 1.6] [Reference Citation Analysis]
2 Wong KY, Yao Q, Yuan LQ, Li Z, Ma ESK, Chim CS. Frequent functional activation of RAS signalling not explained by RAS/RAF mutations in relapsed/refractory multiple myeloma. Sci Rep 2018;8:13522. [PMID: 30201956 DOI: 10.1038/s41598-018-31820-9] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
3 Liu X, Zhao D. CKS1B promotes the progression of hepatocellular carcinoma by activating JAK/STAT3 signal pathway. Anim Cells Syst (Seoul) 2021;25:227-34. [PMID: 34408811 DOI: 10.1080/19768354.2021.1953142] [Reference Citation Analysis]
4 Zhu YS, Liu Z, Min J, Xiong YF. Dexmedetomidine reduces the apoptosis of rat hippocampal neurons via mediating ERK1/2 signal pathway by targeting miR-155. Acta Histochem 2021;123:151734. [PMID: 34048989 DOI: 10.1016/j.acthis.2021.151734] [Reference Citation Analysis]
5 Boyd KD, Pawlyn C, Morgan GJ, Davies FE. Understanding the molecular biology of myeloma and its therapeutic implications. Expert Rev Hematol 2012;5:603-17. [PMID: 23216592 DOI: 10.1586/ehm.12.51] [Cited by in Crossref: 13] [Cited by in F6Publishing: 8] [Article Influence: 1.6] [Reference Citation Analysis]
6 Dolloff NG. Emerging Therapeutic Strategies for Overcoming Proteasome Inhibitor Resistance. Elsevier; 2015. pp. 191-226. [DOI: 10.1016/bs.acr.2015.03.002] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.5] [Reference Citation Analysis]
7 Prideaux SM, Conway O'Brien E, Chevassut TJ. The genetic architecture of multiple myeloma. Adv Hematol 2014;2014:864058. [PMID: 24803933 DOI: 10.1155/2014/864058] [Cited by in Crossref: 47] [Cited by in F6Publishing: 52] [Article Influence: 6.7] [Reference Citation Analysis]
8 Burroughs Garcìa J, Eufemiese RA, Storti P, Sammarelli G, Craviotto L, Todaro G, Toscani D, Marchica V, Giuliani N. Role of 1q21 in Multiple Myeloma: From Pathogenesis to Possible Therapeutic Targets. Cells 2021;10:1360. [PMID: 34205916 DOI: 10.3390/cells10061360] [Reference Citation Analysis]
9 Gu C, Yang Y, Sompallae R, Xu H, Tompkins VS, Holman C, Hose D, Goldschmidt H, Tricot G, Zhan F, Janz S. FOXM1 is a therapeutic target for high-risk multiple myeloma. Leukemia 2016;30:873-82. [PMID: 26648534 DOI: 10.1038/leu.2015.334] [Cited by in Crossref: 28] [Cited by in F6Publishing: 28] [Article Influence: 4.7] [Reference Citation Analysis]
10 Cardona-Benavides IJ, de Ramón C, Gutiérrez NC. Genetic Abnormalities in Multiple Myeloma: Prognostic and Therapeutic Implications. Cells 2021;10:336. [PMID: 33562668 DOI: 10.3390/cells10020336] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
11 Mishra S, Whetstine JR. Different Facets of Copy Number Changes: Permanent, Transient, and Adaptive. Mol Cell Biol 2016;36:1050-63. [PMID: 26755558 DOI: 10.1128/MCB.00652-15] [Cited by in Crossref: 33] [Cited by in F6Publishing: 19] [Article Influence: 6.6] [Reference Citation Analysis]
12 Gonçalves E, Bonduelle O, Soria A, Loulergue P, Rousseau A, Cachanado M, Bonnabau H, Thiebaut R, Tchitchek N, Behillil S, van der Werf S, Vogt A, Simon T, Launay O, Combadière B. Innate gene signature distinguishes humoral versus cytotoxic responses to influenza vaccination. J Clin Invest 2019;129:1960-71. [PMID: 30843873 DOI: 10.1172/JCI125372] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 7.5] [Reference Citation Analysis]
13 Myers AL, Lin L, Nancarrow DJ, Wang Z, Ferrer-Torres D, Thomas DG, Orringer MB, Lin J, Reddy RM, Beer DG, Chang AC. IGFBP2 modulates the chemoresistant phenotype in esophageal adenocarcinoma. Oncotarget 2015;6:25897-916. [PMID: 26317790 DOI: 10.18632/oncotarget.4532] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 3.0] [Reference Citation Analysis]
14 Manier S, Salem KZ, Park J, Landau DA, Getz G, Ghobrial IM. Genomic complexity of multiple myeloma and its clinical implications. Nat Rev Clin Oncol 2017;14:100-13. [DOI: 10.1038/nrclinonc.2016.122] [Cited by in Crossref: 219] [Cited by in F6Publishing: 204] [Article Influence: 43.8] [Reference Citation Analysis]
15 Schmidt TM, Fonseca R, Usmani SZ. Chromosome 1q21 abnormalities in multiple myeloma. Blood Cancer J 2021;11:83. [PMID: 33927196 DOI: 10.1038/s41408-021-00474-8] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
16 Shi G, Zhao C, Fu M, Qiu L. Molecular cloning and expression analysis of the CKS1B gene from black tiger shrimps ( Penaeus monodon ). Aquac Res 2017;48:5133-8. [DOI: 10.1111/are.13159] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
17 Xu L, Fan S, Zhao J, Zhou P, Chu S, Luo J, Wen Q, Chen L, Wen S, Wang L, Shi L. Increased expression of Cks1 protein is associated with lymph node metastasis and poor prognosis in nasopharyngeal carcinoma. Diagn Pathol 2017;12:2. [PMID: 28061788 DOI: 10.1186/s13000-016-0589-9] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
18 Prideaux SM, Conway O'Brien E, Chevassut TJ. The RAG Model: A New Paradigm for Genetic Risk Stratification in Multiple Myeloma. Bone Marrow Res 2014;2014:526568. [PMID: 25295194 DOI: 10.1155/2014/526568] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
19 Lapitz A, Arbelaiz A, O'Rourke CJ, Lavin JL, Casta A, Ibarra C, Jimeno JP, Santos-Laso A, Izquierdo-Sanchez L, Krawczyk M, Perugorria MJ, Jimenez-Aguero R, Sanchez-Campos A, Riaño I, Gónzalez E, Lammert F, Marzioni M, Macias RIR, Marin JJG, Karlsen TH, Bujanda L, Falcón-Pérez JM, Andersen JB, Aransay AM, Rodrigues PM, Banales JM. Patients with Cholangiocarcinoma Present Specific RNA Profiles in Serum and Urine Extracellular Vesicles Mirroring the Tumor Expression: Novel Liquid Biopsy Biomarkers for Disease Diagnosis. Cells 2020;9:E721. [PMID: 32183400 DOI: 10.3390/cells9030721] [Cited by in Crossref: 18] [Cited by in F6Publishing: 20] [Article Influence: 18.0] [Reference Citation Analysis]
20 Huang J, Zhou Y, Thomas GS, Gu Z, Yang Y, Xu H, Tricot G, Zhan F. NEDD8 Inhibition Overcomes CKS1B-Induced Drug Resistance by Upregulation of p21 in Multiple Myeloma. Clin Cancer Res 2015;21:5532-42. [PMID: 26156395 DOI: 10.1158/1078-0432.CCR-15-0254] [Cited by in Crossref: 23] [Cited by in F6Publishing: 14] [Article Influence: 3.8] [Reference Citation Analysis]
21 Tang G, Hidalgo Lopez JE, Wang SA, Hu S, Ma J, Pierce S, Zuo W, Carballo-Zarate AA, Yin CC, Tang Z, Li S, Medeiros LJ, Verstovsek S, Bueso-Ramos CE. Characteristics and clinical significance of cytogenetic abnormalities in polycythemia vera. Haematologica 2017;102:1511-8. [PMID: 28473622 DOI: 10.3324/haematol.2017.165795] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 5.3] [Reference Citation Analysis]
22 Wang H, Sun M, Guo J, Ma L, Jiang H, Gu L, Wen H, Liao S, Chen J, Zeng B, Li Y, Li Y, Yu X, Feng Y, Zhou Y. 3-O-(Z)-coumaroyloleanolic acid overcomes Cks1b-induced chemoresistance in lung cancer by inhibiting Hsp90 and MEK pathways. Biochemical Pharmacology 2017;135:35-49. [DOI: 10.1016/j.bcp.2017.03.007] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
23 Black JC, Atabakhsh E, Kim J, Biette KM, Van Rechem C, Ladd B, Burrowes PD, Donado C, Mattoo H, Kleinstiver BP. Hypoxia drives transient site-specific copy gain and drug-resistant gene expression. Genes Dev. 2015;29:1018-1031. [PMID: 25995187 DOI: 10.1101/gad.259796.115] [Cited by in Crossref: 48] [Cited by in F6Publishing: 46] [Article Influence: 8.0] [Reference Citation Analysis]
24 Salama ME, Du S, Efimova O, Heikal NM, Wendlandt E, Toydemir RM, South S, Perkins SL, Hussong JW, Zhan F. Neoplastic plasma cell aberrant antigen expression patterns and their association with genetic abnormalities. Leuk Lymphoma 2015;56:426-33. [PMID: 24913506 DOI: 10.3109/10428194.2014.931951] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
25 Morelli MB, Offidani M, Alesiani F, Discepoli G, Liberati S, Olivieri A, Santoni M, Santoni G, Leoni P, Nabissi M. The effects of cannabidiol and its synergism with bortezomib in multiple myeloma cell lines. A role for transient receptor potential vanilloid type-2: Cannabidiol Induces Cytotoxicity in Myeloma Cells. Int J Cancer 2014;134:2534-46. [DOI: 10.1002/ijc.28591] [Cited by in Crossref: 48] [Cited by in F6Publishing: 46] [Article Influence: 6.0] [Reference Citation Analysis]
26 Abdi J, Chen G, Chang H. Drug resistance in multiple myeloma: latest findings and new concepts on molecular mechanisms. Oncotarget. 2013;4:2186-2207. [PMID: 24327604 DOI: 10.18632/oncotarget.1497] [Cited by in Crossref: 97] [Cited by in F6Publishing: 94] [Article Influence: 13.9] [Reference Citation Analysis]
27 Shi W, Zhang S, Ma D, Yan D, Zhang G, Cao Y, Wang Z, Wu J, Jiang C. Targeting SphK2 Reverses Acquired Resistance of Regorafenib in Hepatocellular Carcinoma. Front Oncol 2020;10:694. [PMID: 32670862 DOI: 10.3389/fonc.2020.00694] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
28 Wang X, Niu J, Li J, Shen X, Shen S, Straubinger RM, Qu J. Temporal Effects of Combined Birinapant and Paclitaxel on Pancreatic Cancer Cells Investigated via Large-Scale, Ion-Current-Based Quantitative Proteomics (IonStar). Mol Cell Proteomics 2018;17:655-71. [PMID: 29358341 DOI: 10.1074/mcp.RA117.000519] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 3.3] [Reference Citation Analysis]
29 Beldi-Ferchiou A, Skouri N, Ben Ali C, Safra I, Abdelkefi A, Ladeb S, Mrad K, Ben Othman T, Ben Ahmed M. Abnormal repression of SHP-1, SHP-2 and SOCS-1 transcription sustains the activation of the JAK/STAT3 pathway and the progression of the disease in multiple myeloma. PLoS One 2017;12:e0174835. [PMID: 28369102 DOI: 10.1371/journal.pone.0174835] [Cited by in Crossref: 20] [Cited by in F6Publishing: 22] [Article Influence: 5.0] [Reference Citation Analysis]
30 Zhu S, Wang Z, Li Z, Peng H, Luo Y, Deng M, Li R, Dai C, Xu Y, Liu S, Zhang G. Icaritin suppresses multiple myeloma, by inhibiting IL-6/JAK2/STAT3. Oncotarget 2015;6:10460-72. [PMID: 25865044 DOI: 10.18632/oncotarget.3399] [Cited by in Crossref: 43] [Cited by in F6Publishing: 46] [Article Influence: 8.6] [Reference Citation Analysis]
31 Weisberg E, Ray A, Nelson E, Adamia S, Barrett R, Sattler M, Zhang C, Daley JF, Frank D, Fox E, Griffin JD. Reversible resistance induced by FLT3 inhibition: a novel resistance mechanism in mutant FLT3-expressing cells. PLoS One 2011;6:e25351. [PMID: 21980431 DOI: 10.1371/journal.pone.0025351] [Cited by in Crossref: 30] [Cited by in F6Publishing: 28] [Article Influence: 3.0] [Reference Citation Analysis]
32 Huang W, Hu H, Zhang Q, Wu X, Wei F, Yang F, Gan L, Wang N, Yang X, Guo AY. Regulatory networks in mechanotransduction reveal key genes in promoting cancer cell stemness and proliferation. Oncogene 2019;38:6818-34. [PMID: 31406247 DOI: 10.1038/s41388-019-0925-0] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 5.5] [Reference Citation Analysis]
33 Jain AP, Patel K, Pinto S, Radhakrishnan A, Nanjappa V, Kumar M, Raja R, Patil AH, Kumari A, Manoharan M, Karunakaran C, Murugan S, Keshava Prasad TS, Chang X, Mathur PP, Kumar P, Gupta R, Gupta R, Khanna-Gupta A, Sidransky D, Chatterjee A, Gowda H. MAP2K1 is a potential therapeutic target in erlotinib resistant head and neck squamous cell carcinoma. Sci Rep 2019;9:18793. [PMID: 31827134 DOI: 10.1038/s41598-019-55208-5] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
34 Anbazhagan K, Duroux-Richard I, Jorgensen C, Apparailly F. Transcriptomic network support distinct roles of classical and non-classical monocytes in human. Int Rev Immunol 2014;33:470-89. [PMID: 24730730 DOI: 10.3109/08830185.2014.902453] [Cited by in Crossref: 27] [Cited by in F6Publishing: 29] [Article Influence: 3.9] [Reference Citation Analysis]
35 Zeng Z, Gao ZL, Zhang ZP, Jiang HB, Yang CQ, Yang J, Xia XB. Downregulation of CKS1B restrains the proliferation, migration, invasion and angiogenesis of retinoblastoma cells through the MEK/ERK signaling pathway. Int J Mol Med 2019;44:103-14. [PMID: 31115482 DOI: 10.3892/ijmm.2019.4183] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 3.5] [Reference Citation Analysis]
36 Demidenko ZN, McCubrey JA. Recent progress in targeting cancer. Aging (Albany NY) 2011;3:1154-62. [PMID: 22228887 DOI: 10.18632/aging.100421] [Cited by in Crossref: 4] [Cited by in F6Publishing: 7] [Article Influence: 0.4] [Reference Citation Analysis]
37 Ma J, Liu S, Wang Y. MicroRNA-21 and multiple myeloma: small molecule and big function. Med Oncol. 2014;31:94. [PMID: 24981236 DOI: 10.1007/s12032-014-0094-5] [Cited by in Crossref: 15] [Cited by in F6Publishing: 17] [Article Influence: 2.1] [Reference Citation Analysis]
38 Amodio N, Bellizzi D, Leotta M, Raimondi L, Biamonte L, D'Aquila P, Di Martino MT, Calimeri T, Rossi M, Lionetti M, Leone E, Passarino G, Neri A, Giordano A, Tagliaferri P, Tassone P. miR-29b induces SOCS-1 expression by promoter demethylation and negatively regulates migration of multiple myeloma and endothelial cells. Cell Cycle 2013;12:3650-62. [PMID: 24091729 DOI: 10.4161/cc.26585] [Cited by in Crossref: 74] [Cited by in F6Publishing: 67] [Article Influence: 9.3] [Reference Citation Analysis]
39 Nguyen DD, Lee DG, Kim S, Kang K, Rhee JK, Chang S. Integrative Bioinformatics and Functional Analyses of GEO, ENCODE, and TCGA Reveal FADD as a Direct Target of the Tumor Suppressor BRCA1. Int J Mol Sci 2018;19:E1458. [PMID: 29757984 DOI: 10.3390/ijms19051458] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
40 Passamonti F, Maffioli M, Caramazza D, Cazzola M. Myeloproliferative neoplasms: from JAK2 mutations discovery to JAK2 inhibitor therapies. Oncotarget 2011;2:485-90. [PMID: 21646683 DOI: 10.18632/oncotarget.281] [Cited by in Crossref: 25] [Cited by in F6Publishing: 32] [Article Influence: 2.5] [Reference Citation Analysis]
41 Yu W, Guo R, Qu X, Qiu H, Li J, Zhang R, Chen L. The amplification of 1q21 is an adverse prognostic factor in patients with multiple myeloma in a Chinese population. Onco Targets Ther 2016;9:295-302. [PMID: 26834489 DOI: 10.2147/OTT.S95381] [Cited by in Crossref: 1] [Cited by in F6Publishing: 6] [Article Influence: 0.2] [Reference Citation Analysis]
42 Lu DY, Sun J, Zheng J, Zheng L, Xue WN, Li C, He B, Wang YL, Li YJ, Liu T. Shenxiong glucose injection inhibits H2O2-induced H9c2 cell apoptosis by activating the ERK signaling pathway. Biomed Pharmacother 2021;143:112114. [PMID: 34474350 DOI: 10.1016/j.biopha.2021.112114] [Reference Citation Analysis]
43 Dehghanifard A, Kaviani S, Abroun S, Mehdizadeh M, Saiedi S, Maali A, Ghaffari S, Azad M. Various Signaling Pathways in Multiple Myeloma Cells and Effects of Treatment on These Pathways. Clin Lymphoma Myeloma Leuk 2018;18:311-20. [PMID: 29606369 DOI: 10.1016/j.clml.2018.03.007] [Cited by in Crossref: 16] [Cited by in F6Publishing: 18] [Article Influence: 5.3] [Reference Citation Analysis]
44 Gu C, Peng H, Lu Y, Yang H, Tian Z, Yin G, Zhang W, Lu S, Zhang Y, Yang Y. BTK suppresses myeloma cellular senescence through activating AKT/P27/Rb signaling. Oncotarget 2017;8:56858-67. [PMID: 28915637 DOI: 10.18632/oncotarget.18096] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
45 Wang Z, Inuzuka H, Zhong J, Liu P, Sarkar FH, Sun Y, Wei W. Identification of acetylation-dependent regulatory mechanisms that govern the oncogenic functions of Skp2. Oncotarget 2012;3:1294-300. [PMID: 23230084 DOI: 10.18632/oncotarget.740] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 2.6] [Reference Citation Analysis]
46 Jiang Y, Saga K, Miyamoto Y, Kaneda Y. Cytoplasmic calcium increase via fusion with inactivated Sendai virus induces apoptosis in human multiple myeloma cells by downregulation of c-Myc oncogene. Oncotarget 2016;7:36034-48. [PMID: 27145280 DOI: 10.18632/oncotarget.9105] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
47 Han Z, Wang X, Ma L, Chen L, Xiao M, Huang L, Cao Y, Bai J, Ma D, Zhou J, Hong Z. Inhibition of STAT3 signaling targets both tumor-initiating and differentiated cell populations in prostate cancer. Oncotarget 2014;5:8416-28. [PMID: 25261365 DOI: 10.18632/oncotarget.2314] [Cited by in Crossref: 43] [Cited by in F6Publishing: 41] [Article Influence: 7.2] [Reference Citation Analysis]
48 Kumar S, Sharawat SK. Epigenetic regulators of programmed death-ligand 1 expression in human cancers. Transl Res 2018;202:129-45. [PMID: 30401465 DOI: 10.1016/j.trsl.2018.05.011] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 6.3] [Reference Citation Analysis]
49 Vicente-Dueñas C, González-Herrero I, García Cenador MB, García Criado FJ, Sánchez-García I. Loss of p53 exacerbates multiple myeloma phenotype by facilitating the reprogramming of hematopoietic stem/progenitor cells to malignant plasma cells by MafB. Cell Cycle 2012;11:3896-900. [PMID: 22983007 DOI: 10.4161/cc.22186] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 2.0] [Reference Citation Analysis]
50 Weißbach S, Langer C, Puppe B, Nedeva T, Bach E, Kull M, Bargou R, Einsele H, Rosenwald A, Knop S, Leich E. The molecular spectrum and clinical impact of DIS3 mutations in multiple myeloma. Br J Haematol 2015;169:57-70. [PMID: 25521164 DOI: 10.1111/bjh.13256] [Cited by in Crossref: 36] [Cited by in F6Publishing: 33] [Article Influence: 5.1] [Reference Citation Analysis]
51 Yang Y, Gu C, Luo C, Li F, Wang M. BUB1B promotes multiple myeloma cell proliferation through CDC20/CCNB axis. Med Oncol 2015;32:81. [PMID: 25698537 DOI: 10.1007/s12032-015-0542-x] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 1.7] [Reference Citation Analysis]
52 Yang Y, Zhou W, Xia J, Gu Z, Wendlandt E, Zhan X, Janz S, Tricot G, Zhan F. NEK2 mediates ALDH1A1-dependent drug resistance in multiple myeloma. Oncotarget 2014;5:11986-97. [PMID: 25230277 DOI: 10.18632/oncotarget.2388] [Cited by in Crossref: 34] [Cited by in F6Publishing: 36] [Article Influence: 5.7] [Reference Citation Analysis]
53 Yue Y, Wang Y, He Y, Yang S, Chen Z, Wang Y, Xing S, Shen C, Amin HM, Wu D, Song YH. Reversal of bortezomib resistance in myelodysplastic syndrome cells by MAPK inhibitors. PLoS One 2014;9:e90992. [PMID: 24608798 DOI: 10.1371/journal.pone.0090992] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
54 Yang Y, Shi J, Gu Z, Salama ME, Das S, Wendlandt E, Xu H, Huang J, Tao Y, Hao M, Franqui R, Levasseur D, Janz S, Tricot G, Zhan F. Bruton tyrosine kinase is a therapeutic target in stem-like cells from multiple myeloma. Cancer Res 2015;75:594-604. [PMID: 25589346 DOI: 10.1158/0008-5472.CAN-14-2362] [Cited by in Crossref: 47] [Cited by in F6Publishing: 30] [Article Influence: 7.8] [Reference Citation Analysis]
55 Chen ZM, Huang L, Li MM, Meng L, Ying SC, Xu AM. Inhibitory effects of isocryptotanshinone on gastric cancer. Sci Rep. 2018;8:9307. [PMID: 29915371 DOI: 10.1038/s41598-018-27638-0] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.7] [Reference Citation Analysis]
56 Khattar V, Thottassery JV. Cks1: Structure, Emerging Roles and Implications in Multiple Cancers. J Cancer Ther 2013;4:1341-54. [PMID: 24563807 DOI: 10.4236/jct.2013.48159] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 2.4] [Reference Citation Analysis]
57 Zhang W, Gao Z, Guan M, Liu N, Meng F, Wang G. ASF1B Promotes Oncogenesis in Lung Adenocarcinoma and Other Cancer Types. Front Oncol 2021;11:731547. [PMID: 34568067 DOI: 10.3389/fonc.2021.731547] [Reference Citation Analysis]
58 Kraus M, Bader J, Overkleeft H, Driessen C. Nelfinavir augments proteasome inhibition by bortezomib in myeloma cells and overcomes bortezomib and carfilzomib resistance. Blood Cancer J 2013;3:e103. [PMID: 23454896 DOI: 10.1038/bcj.2013.2] [Cited by in Crossref: 30] [Cited by in F6Publishing: 33] [Article Influence: 3.8] [Reference Citation Analysis]
59 Nelson EA, Sharma SV, Settleman J, Frank DA. A chemical biology approach to developing STAT inhibitors: molecular strategies for accelerating clinical translation. Oncotarget 2011;2:518-24. [PMID: 21680956 DOI: 10.18632/oncotarget.296] [Cited by in Crossref: 62] [Cited by in F6Publishing: 61] [Article Influence: 6.2] [Reference Citation Analysis]
60 Wang H, Zhang Z, Yan Z, Ma S. CKS1B promotes cell proliferation and invasion by activating STAT3/PD-L1 and phosphorylation of Akt signaling in papillary thyroid carcinoma. J Clin Lab Anal 2021;35:e23565. [PMID: 32960462 DOI: 10.1002/jcla.23565] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
61 Cui Y, Liu Y, Wang D, Liu Y, Liu L, Fang B. Comparative Analysis of miRNA Expression Profiles of Multiple Myeloma with 1q21 Gains and Normal FISH. Acta Haematol 2018;139:96-100. [PMID: 29402764 DOI: 10.1159/000486662] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
62 Davis LN, Sherbenou DW. Emerging Therapeutic Strategies to Overcome Drug Resistance in Multiple Myeloma. Cancers (Basel) 2021;13:1686. [PMID: 33918370 DOI: 10.3390/cancers13071686] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
63 Shi W, Huang Q, Xie J, Wang H, Yu X, Zhou Y. CKS1B as Drug Resistance-Inducing Gene-A Potential Target to Improve Cancer Therapy. Front Oncol 2020;10:582451. [PMID: 33102238 DOI: 10.3389/fonc.2020.582451] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
64 Yang JG, Lu R, Ye XJ, Zhang J, Tan YQ, Zhou G. Icaritin Reduces Oral Squamous Cell Carcinoma Progression via the Inhibition of STAT3 Signaling. Int J Mol Sci 2017;18:E132. [PMID: 28085115 DOI: 10.3390/ijms18010132] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 3.0] [Reference Citation Analysis]
65 Stella F, Pedrazzini E, Baialardo E, Fantl DB, Schutz N, Slavutsky I. Quantitative analysis of CKS1B mRNA expression and copy number gain in patients with plasma cell disorders. Blood Cells Mol Dis 2014;53:110-7. [PMID: 24973170 DOI: 10.1016/j.bcmd.2014.05.006] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 1.1] [Reference Citation Analysis]
66 Song L, Zhang S, Yu S, Ma F, Wang B, Zhang C, Sun J, Mao X, Wei L. Cellular heterogeneity landscape in laryngeal squamous cell carcinoma. Int J Cancer 2020;147:2879-90. [PMID: 32638385 DOI: 10.1002/ijc.33192] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 5.0] [Reference Citation Analysis]
67 McCubrey JA, Steelman LS, Chappell WH, Sun L, Davis NM, Abrams SL, Franklin RA, Cocco L, Evangelisti C, Chiarini F, Martelli AM, Libra M, Candido S, Ligresti G, Malaponte G, Mazzarino MC, Fagone P, Donia M, Nicoletti F, Polesel J, Talamini R, Bäsecke J, Mijatovic S, Maksimovic-Ivanic D, Michele M, Tafuri A, Dulińska-Litewka J, Laidler P, D'Assoro AB, Drobot L, Umezawa D, Montalto G, Cervello M, Demidenko ZN. Advances in targeting signal transduction pathways. Oncotarget 2012;3:1505-21. [PMID: 23455493 DOI: 10.18632/oncotarget.802] [Cited by in Crossref: 31] [Cited by in F6Publishing: 34] [Article Influence: 3.9] [Reference Citation Analysis]
68 Nguyen P, Chakrabarti J, Li Y, Kalim KW, Zhang M, Zhang L, Zheng Y, Guo F. Rational Targeting of Cdc42 Overcomes Drug Resistance of Multiple Myeloma. Front Oncol 2019;9:958. [PMID: 31632904 DOI: 10.3389/fonc.2019.00958] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
69 Black JC, Whetstine JR. Too little O2 Too much gain. Cell Cycle 2015;14:2869-70. [PMID: 26221746 DOI: 10.1080/15384101.2015.1076659] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
70 Black JC, Zhang H, Kim J, Getz G, Whetstine JR. Regulation of Transient Site-specific Copy Gain by MicroRNA. J Biol Chem 2016;291:4862-71. [PMID: 26755726 DOI: 10.1074/jbc.M115.711648] [Cited by in Crossref: 17] [Cited by in F6Publishing: 13] [Article Influence: 3.4] [Reference Citation Analysis]
71 Fujita Y, Yagishita S, Hagiwara K, Yoshioka Y, Kosaka N, Takeshita F, Fujiwara T, Tsuta K, Nokihara H, Tamura T, Asamura H, Kawaishi M, Kuwano K, Ochiya T. The clinical relevance of the miR-197/CKS1B/STAT3-mediated PD-L1 network in chemoresistant non-small-cell lung cancer. Mol Ther 2015;23:717-27. [PMID: 25597412 DOI: 10.1038/mt.2015.10] [Cited by in Crossref: 143] [Cited by in F6Publishing: 160] [Article Influence: 23.8] [Reference Citation Analysis]
72 Tsubaki M, Takeda T, Tomonari Y, Mashimo K, Koumoto YI, Hoshida S, Itoh T, Imano M, Satou T, Sakaguchi K, Nishida S. The MIP-1α autocrine loop contributes to decreased sensitivity to anticancer drugs. J Cell Physiol 2018;233:4258-71. [PMID: 29057477 DOI: 10.1002/jcp.26245] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 3.0] [Reference Citation Analysis]
73 Haagenson KK, Zhang JW, Xu Z, Shekhar MP, Wu GS. Functional analysis of MKP-1 and MKP-2 in breast cancer tamoxifen sensitivity. Oncotarget 2014;5:1101-10. [PMID: 24658355 DOI: 10.18632/oncotarget.1795] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
74 Ichikawa S, Fukuhara N, Hatta S, Himuro M, Nasu K, Ono K, Okitsu Y, Kobayashi M, Onishi Y, Ri M, Ichinohasama R, Harigae H. Anaplastic multiple myeloma: possible limitations of conventional chemotherapy for long-term remission. J Clin Exp Hematop 2018;58:39-42. [PMID: 29553093 DOI: 10.3960/jslrt.17035] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 2.3] [Reference Citation Analysis]